Trial Profile
Pharmacotherapy of cognitive deficits in schizophrenic disorders: a randomised placebo-controlled double-blind study of tolcapone versus pergolide.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2019
Price :
$35
*
At a glance
- Drugs Tolcapone (Primary) ; Pergolide
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms TOCTAP
- 05 Dec 2019 Status changed from completed to discontinued.
- 02 Oct 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 17 Apr 2010 New trial record